|
Mechanism Research of Chonglou as a Pain Killer by Network Pharmacology |
|
View Full Text View/Add Comment Download reader |
DOI:10.4103/wjtcm.wjtcm_84_20 |
KeyWord:Chonglou, molecular docking, network pharmacology, pain |
Author | Institution |
Yu‑Tong Liuab |
a.Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University; b.International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of Pharmacy, Jinan University, Guangzhou, Guangdong |
Yong‑Li Situab |
a.Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University; b.International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of Pharmacy, Jinan University, Guangzhou, Guangdong |
Ting‑Ting Zhaoab |
a.Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University; b.International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of Pharmacy, Jinan University, Guangzhou, Guangdong |
Li‑Na Longab |
a.Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University; b.International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of Pharmacy, Jinan University, Guangzhou, Guangdong |
He‑Kun Zengab |
a.Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University; b.International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of Pharmacy, Jinan University, Guangzhou, Guangdong |
Shang‑Dong Liangc |
c.Department of Physiology, Medical College of Nanchang University, Nanchang, Jiangxi, China |
Günther Schmalzingd |
d.Deparment of Molecular Pharmacology, RWTH Aachen University, Aachen, Germany |
Hong‑Wei Gaoe |
e.Department of biological Pharmaceuticals, School of Life Science, Ludong University, Yantai, Shandong, |
Jin‑Bin Weif |
f.Department of Pharmaceutical Experimental Center, College of Pharmacy, Guangxi Medical University, Nanning, Guangxi, China |
Chuan‑Hua Heg |
g.Department of Medical Science, Brown University, Providence, Rhode Island, USA |
Hong Nieab |
a.Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University; b.International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of Pharmacy, Jinan University, Guangzhou, Guangdong |
|
Hits: 1034 |
Download times: 1026 |
Abstract: |
Objective: The objective of this study is to screen the therapeutic targets of pain of traditional Chinese medicine Chonglou and explore the
relevant mechanism by network pharmacology techniques and methods. Materials and Methods: The chemical components of Chonglou were
collected according to chemistry database and related literature. SwissADME was used to collect the potential active ingredients from all the
chemical components of Chonglou and SwissTarget Prediction was utilized to predict their targets. The genes related to pain were collected
from GeneCards and Online Mendelian Inheritance in Man databases. Joint genes were uploaded to the online string database for the analysis
and the PPI network was constructed. The “Chonglou-active component-target-pain” network was constructed by Cytoscape 3.7.1 software,
Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis
were performed for key target proteins. The top three active components with most targets in the network were docked with the target proteins
by the molecular docking technique. Results: A total of nine potential active compounds of Chonglou, 264 potential target genes, 2385 targets
of pain disorder, and 128 common targets for drug and disease were screened. One hundred and thirty‑one GO items were identified by the GO
enrichment analysis, and 23 related signaling pathways were identified by the KEGG pathway enrichment analysis. Molecular‑docking results
show that pennogenin is the optimal butt ligand of PIK3CA, STAT3, mitogen‑activated protein kinase 14, and ADORA1. Conclusion: It is
preliminarily revealed that Chonglou might treat pain through multiple targets, multiple biology processes and multiple pain-related signaling
pathways, providing reference for the subsequent experimental research. |
Close |
|
|
|